Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
During crashes, passive index funds typically deliver steadier exposure and lower fees, while active funds may outperform briefly but incur higher risks and costs.
24,770 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
A mid-size fund reduced its TriMas stake by about $5 million after a strong run, but didn’t exit the position entirel...
A dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
A strong pharma dividend stock could be a powerful component of a retirement plan. Learn how to choose, invest, and c...
March 2026 brings tighter rules and sharper competition among binary options platforms. This report identifies the be...
Nvidia's CEO argues the AI data-center expansion is only beginning, with trillions more in infrastructure needed. Mar...
As automation accelerates, ex-presidential candidate Andrew Yang revives a bold tax idea: shift the burden from labor...
After Microsoft's pullback, savvy investors look for durable megacap ideas. This guide highlights three top megacap s...
The Supreme Court looks poised to restrict late mail ballots, a move that could impact voter turnout and state electi...
A prominent market strategist says investors should their money in gold, proposing a 10% allocation to hedge inflatio...
BridgeBio's Q1 2026 earnings narrative is more than quarterly numbers—it's a roadmap for the year ahead. This guide e...
RAD Intel debuts a Regulation A+ offering at $0.91 per share, pitching an AI-driven marketing engine as the next oppo...